368 related articles for article (PubMed ID: 25175806)
1. Drugging MYCN through an allosteric transition in Aurora kinase A.
Gustafson WC; Meyerowitz JG; Nekritz EA; Chen J; Benes C; Charron E; Simonds EF; Seeger R; Matthay KK; Hertz NT; Eilers M; Shokat KM; Weiss WA
Cancer Cell; 2014 Sep; 26(3):414-427. PubMed ID: 25175806
[TBL] [Abstract][Full Text] [Related]
2. Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma.
Felgenhauer J; Tomino L; Selich-Anderson J; Bopp E; Shah N
Neoplasia; 2018 Oct; 20(10):965-974. PubMed ID: 30153557
[TBL] [Abstract][Full Text] [Related]
3. PHA-680626 Is an Effective Inhibitor of the Interaction between Aurora-A and N-Myc.
Boi D; Souvalidou F; Capelli D; Polverino F; Marini G; Montanari R; Pochetti G; Tramonti A; Contestabile R; Trisciuoglio D; Carpinelli P; Ascanelli C; Lindon C; De Leo A; Saviano M; Di Santo R; Costi R; Guarguaglini G; Paiardini A
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884931
[TBL] [Abstract][Full Text] [Related]
4. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
[TBL] [Abstract][Full Text] [Related]
5. Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors.
Richards MW; Burgess SG; Poon E; Carstensen A; Eilers M; Chesler L; Bayliss R
Proc Natl Acad Sci U S A; 2016 Nov; 113(48):13726-13731. PubMed ID: 27837025
[TBL] [Abstract][Full Text] [Related]
6. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.
Faisal A; Vaughan L; Bavetsias V; Sun C; Atrash B; Avery S; Jamin Y; Robinson SP; Workman P; Blagg J; Raynaud FI; Eccles SA; Chesler L; Linardopoulos S
Mol Cancer Ther; 2011 Nov; 10(11):2115-23. PubMed ID: 21885865
[TBL] [Abstract][Full Text] [Related]
7. Optimization of ligand and lipophilic efficiency to identify an in vivo active furano-pyrimidine Aurora kinase inhibitor.
Shiao HY; Coumar MS; Chang CW; Ke YY; Chi YH; Chu CY; Sun HY; Chen CH; Lin WH; Fung KS; Kuo PC; Huang CT; Chang KY; Lu CT; Hsu JT; Chen CT; Jiaang WT; Chao YS; Hsieh HP
J Med Chem; 2013 Jul; 56(13):5247-60. PubMed ID: 23808327
[TBL] [Abstract][Full Text] [Related]
8. Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma.
Brockmann M; Poon E; Berry T; Carstensen A; Deubzer HE; Rycak L; Jamin Y; Thway K; Robinson SP; Roels F; Witt O; Fischer M; Chesler L; Eilers M
Cancer Cell; 2013 Jul; 24(1):75-89. PubMed ID: 23792191
[TBL] [Abstract][Full Text] [Related]
9. Targeting GD2 ganglioside and aurora A kinase as a dual strategy leading to cell death in cultures of human neuroblastoma cells.
Horwacik I; Durbas M; Boratyn E; Węgrzyn P; Rokita H
Cancer Lett; 2013 Dec; 341(2):248-64. PubMed ID: 23962557
[TBL] [Abstract][Full Text] [Related]
10. Discovery and Synthesis of a Pyrimidine-Based Aurora Kinase Inhibitor to Reduce Levels of MYC Oncoproteins.
Chi YH; Yeh TK; Ke YY; Lin WH; Tsai CH; Wang WP; Chen YT; Su YC; Wang PC; Chen YF; Wu ZW; Yeh JY; Hung MC; Wu MH; Wang JY; Chen CP; Song JS; Shih C; Chen CT; Chang CP
J Med Chem; 2021 Jun; 64(11):7312-7330. PubMed ID: 34009981
[TBL] [Abstract][Full Text] [Related]
11. A moving target: structure and disorder in pursuit of Myc inhibitors.
Bayliss R; Burgess SG; Leen E; Richards MW
Biochem Soc Trans; 2017 Jun; 45(3):709-717. PubMed ID: 28620032
[TBL] [Abstract][Full Text] [Related]
12. A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.
Dauch D; Rudalska R; Cossa G; Nault JC; Kang TW; Wuestefeld T; Hohmeyer A; Imbeaud S; Yevsa T; Hoenicke L; Pantsar T; Bozko P; Malek NP; Longerich T; Laufer S; Poso A; Zucman-Rossi J; Eilers M; Zender L
Nat Med; 2016 Jul; 22(7):744-53. PubMed ID: 27213815
[TBL] [Abstract][Full Text] [Related]
13. TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways.
Miura A; Sootome H; Fujita N; Suzuki T; Fukushima H; Mizuarai S; Masuko N; Ito K; Hashimoto A; Uto Y; Sugimoto T; Takahashi H; Mitsuya M; Hirai H
Invest New Drugs; 2021 Jun; 39(3):724-735. PubMed ID: 33409897
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylation, Mg-ADP, and Inhibitors Differentially Shape the Conformational Dynamics of the A-Loop of Aurora-A.
Musavizadeh Z; Grottesi A; Guarguaglini G; Paiardini A
Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33921540
[TBL] [Abstract][Full Text] [Related]
15. BPR1K653, a novel Aurora kinase inhibitor, exhibits potent anti-proliferative activity in MDR1 (P-gp170)-mediated multidrug-resistant cancer cells.
Cheung CH; Lin WH; Hsu JT; Hour TC; Yeh TK; Ko S; Lien TW; Coumar MS; Liu JF; Lai WY; Shiao HY; Lee TR; Hsieh HP; Chang JY
PLoS One; 2011; 6(8):e23485. PubMed ID: 21887256
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib suppress neuroblastoma growth through degradation of MYCN and inhibition of angiogenesis.
Calero R; Morchon E; Johnsen JI; Serrano R
PLoS One; 2014; 9(4):e95628. PubMed ID: 24759734
[TBL] [Abstract][Full Text] [Related]
17. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
Moore NF; Azarova AM; Bhatnagar N; Ross KN; Drake LE; Frumm S; Liu QS; Christie AL; Sanda T; Chesler L; Kung AL; Gray NS; Stegmaier K; George RE
Oncotarget; 2014 Sep; 5(18):8737-49. PubMed ID: 25228590
[TBL] [Abstract][Full Text] [Related]
18. Targeting MYCN in neuroblastoma by BET bromodomain inhibition.
Puissant A; Frumm SM; Alexe G; Bassil CF; Qi J; Chanthery YH; Nekritz EA; Zeid R; Gustafson WC; Greninger P; Garnett MJ; McDermott U; Benes CH; Kung AL; Weiss WA; Bradner JE; Stegmaier K
Cancer Discov; 2013 Mar; 3(3):308-23. PubMed ID: 23430699
[TBL] [Abstract][Full Text] [Related]
19. Targeting of the MYCN protein with small molecule c-MYC inhibitors.
Müller I; Larsson K; Frenzel A; Oliynyk G; Zirath H; Prochownik EV; Westwood NJ; Henriksson MA
PLoS One; 2014; 9(5):e97285. PubMed ID: 24859015
[TBL] [Abstract][Full Text] [Related]
20. Switching Aurora-A kinase on and off at an allosteric site.
Bayliss R; Burgess SG; McIntyre PJ
FEBS J; 2017 Sep; 284(18):2947-2954. PubMed ID: 28342286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]